Any current/future new fundraising through debt or equity?

No specific mention of new fundraising through debt or equity in the transcript. The company reported that for the full year FY26, they did not utilize any working capital limits except letters of credit and bank guarantees. Capex for FY26 was INR152 crores funded internally, focusing on Ambernath and smaller projects. For the Patalganga facility, an estimated capex of INR200 crores is planned over the next 2 years. No discussion on raising new debt or equity to fund this; emphasis appears on internal accruals and disciplined financial management. Overall, no indication or announcement of fres

Any current/future capex/capital investment/strategic investment?

Continued capacity expansion with the addition of the F block at Lote Parshuram plant, adding 150-200 KL capacity over the next 2 years with INR40-50 crores capex. Development of the Patalganga facility with all clearances received; Phase 1 includes two API/advanced intermediate blocks and two formulation blocks, planned capex around INR200 crores over the next 2 years. Focus on capacity building to support growth, especially for CMO/CDMO opportunities and to handle scaling product volumes. Total capex for FY26 was INR152 crores, mainly spent on Ambernath facility, maintenance, Ribo Bloc

Future growth expectations in sales/revenue/volumes?

Supriya Lifescience targets approximately 20% annual revenue growth, aiming to achieve INR 1,000 crores by FY27. Growth driven by sustained demand in core therapeutic segments: anesthetics, antibiotics, anti-anxiety, vitamins, and ADHD. Plan to launch 3 to 4 new products annually, including 2 new launches each in anesthetics and ADHD segments in FY27. Cardiovascular advanced intermediate product scaling up, expected to contribute increasingly over 2-3 years. New capacities from debottlenecking and new blocks (F block and expansions) will add 150-200 KL over 2 years to support growth. Backward

Future growth expectations in earnings/operating earnings/profits/EPS?

Supriya Lifescience targets approximately 20% annual revenue growth, aiming to reach INR1,000 crores by FY27. EBITDA margins are expected to remain stable in the 33%-35% range over the next 5-6 years. Growth will be driven by new product launches (3-4 annually), expanding regulated market exposure, and capacity expansions at Ambernath and Patalganga facilities. R&D investments have doubled, focusing on niche APIs, CMO/CDMO opportunities, and finished formulations like liquid anesthetics and injectables. Operating leverage expected to improve once Ambernath and Patalganga facilities are fully o

Current/ Expected Orderbook/ Pending Orders?

Cardiovascular intermediate: Advanced discussions for 300 metric tons capacity, expected to be nearly fully utilized in FY27, but full potential to scale over 2-3 years. Contracts locked with 3-4 large customers for the cardiovascular product. Liquid anesthetic (sevoflurane formulation): CMO discussions at advanced stage, but no firm term sheet signed yet. DSM contract stabilized with around 3 tons/month volume; contributing approx. INR30-35 crores in FY26 with peak expected at INR60 crores in FY27. No signed agreement yet for GLP-1 product development; discussions are at an advanced stage. Ne

Supriya Lifesci.Q4 FY26

Supriya Lifesci. Q4 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹795P/E: 32.6Market Cap: ₹6.5K Cr

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→Supriya Lifescience targets approximately 20% annual revenue growth, aiming to achieve INR 1,000 crores by FY27.
→Growth driven by sustained demand in core therapeutic segments: anesthetics, antibiotics, anti-anxiety, vitamins, and ADHD.
→Plan to launch 3 to 4 new products annually, including 2 new launches each in anesthetics and ADHD segments in FY27.
→Cardiovascular advanced intermediate product scaling up, expected to contribute increasingly over 2-3 years.
→New capacities from debottlenecking and new blocks (F block and expansions) will add 150-200 KL over 2 years to support growth.
→Backward integration completed to support scalability and cost efficiency.
→Ambernath and upcoming Patalganga facilities expected to accelerate growth beyond FY27.
→Growth in U.S. market exposure expected to increase over next 3-4 years through new product launches.
→EBITDA margin guidance maintained at 33% to 35%, supporting profitable expansion.

Margin guidance

Category 3

→Supriya Lifescience targets approximately 20% annual revenue growth, aiming to reach INR1,000 crores by FY27.
→EBITDA margins are expected to remain stable in the 33%-35% range over the next 5-6 years.
→Growth will be driven by new product launches (3-4 annually), expanding regulated market exposure, and capacity expansions at Ambernath and Patalganga facilities.
→R&D investments have doubled, focusing on niche APIs, CMO/CDMO opportunities, and finished formulations like liquid anesthetics and injectables.
→Operating leverage expected to improve once Ambernath and Patalganga facilities are fully operational, supporting scale-up and margin stability.
→Cash flow conversion may improve as inventory days normalize post backward integration scale-up.
→EPS growth is aligned with revenue and margin growth, supported by disciplined cost management and expanding exports, especially in Europe and LATAM.

3 more insights locked — sign up free to unlock

Fundraise plans

→No specific mention of new fundraising through debt or equity in the transcript.
→The company reported that for the full year FY26, they did not utilize any working capital limits except letters of credit and bank guarantees.
→Capex for FY26 was INR152 crores funded internally, focusing on Ambernath and smaller projects.
→For the Patalganga facility, an estimated capex of INR200 crores is planned over the next 2 years.
→No discussion on raising new debt or equity to fund this; emphasis appears on internal accruals and disciplined financial management.
→Overall, no indication or announcement of fresh fundraising via debt or equity in the near term from the transcripts provided.

Order book

Yes

→Cardiovascular intermediate: Advanced discussions for 300 metric tons capacity, expected to be nearly fully utilized in FY27, but full potential to scale over 2-3 years.
→Contracts locked with 3-4 large customers for the cardiovascular product.
→Liquid anesthetic (sevoflurane formulation): CMO discussions at advanced stage, but no firm term sheet signed yet.
→DSM contract stabilized with around 3 tons/month volume; contributing approx. INR30-35 crores in FY26 with peak expected at INR60 crores in FY27.
→No signed agreement yet for GLP-1 product development; discussions are at an advanced stage.
→New product launches and existing basket growing steadily.
→No use of PLI scheme; focusing on customer qualification and dossier inclusion.
→Order book for cardiovascular and other products contributing to gradual scale-up but no immediate large jumps in revenue for FY27 from new technologies/products.

Capex plans

Yes

→Continued capacity expansion with the addition of the F block at Lote Parshuram plant, adding 150-200 KL capacity over the next 2 years with INR40-50 crores capex.
→Development of the Patalganga facility with all clearances received; Phase 1 includes two API/advanced intermediate blocks and two formulation blocks, planned capex around INR200 crores over the next 2 years.
→Focus on capacity building to support growth, especially for CMO/CDMO opportunities and to handle scaling product volumes.
→Total capex for FY26 was INR152 crores, mainly spent on Ambernath facility, maintenance, Ribo Block, and formulation plant needs.
→R&D investments have doubled with new labs at Lote and Ambernath focusing on new APIs, formulations, and CMO/CDMO areas.
→Further capex expected to support backing integration, new product launches, and strategic growth segments like cardiovascular and anesthetics.

How does Supriya Lifesci. rank vs peers in ?

Pro feature

1Supriya Lifesci.

Rev 2Mar 3

See full sector rankings

Supriya Lifesci.Q4 FY26

Supriya Lifesci. Q4 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹795P/E: 32.6Market Cap: ₹6.5K Cr

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→Supriya Lifescience targets approximately 20% annual revenue growth, aiming to achieve INR 1,000 crores by FY27.
→Growth driven by sustained demand in core therapeutic segments: anesthetics, antibiotics, anti-anxiety, vitamins, and ADHD.
→Plan to launch 3 to 4 new products annually, including 2 new launches each in anesthetics and ADHD segments in FY27.
→Cardiovascular advanced intermediate product scaling up, expected to contribute increasingly over 2-3 years.
→New capacities from debottlenecking and new blocks (F block and expansions) will add 150-200 KL over 2 years to support growth.
→Backward integration completed to support scalability and cost efficiency.
→Ambernath and upcoming Patalganga facilities expected to accelerate growth beyond FY27.
→Growth in U.S. market exposure expected to increase over next 3-4 years through new product launches.
→EBITDA margin guidance maintained at 33% to 35%, supporting profitable expansion.

Margin guidance

Category 3

→Supriya Lifescience targets approximately 20% annual revenue growth, aiming to reach INR1,000 crores by FY27.
→EBITDA margins are expected to remain stable in the 33%-35% range over the next 5-6 years.
→Growth will be driven by new product launches (3-4 annually), expanding regulated market exposure, and capacity expansions at Ambernath and Patalganga facilities.
→R&D investments have doubled, focusing on niche APIs, CMO/CDMO opportunities, and finished formulations like liquid anesthetics and injectables.
→Operating leverage expected to improve once Ambernath and Patalganga facilities are fully operational, supporting scale-up and margin stability.
→Cash flow conversion may improve as inventory days normalize post backward integration scale-up.
→EPS growth is aligned with revenue and margin growth, supported by disciplined cost management and expanding exports, especially in Europe and LATAM.

3 more insights locked — sign up free to unlock

Fundraise plans

→No specific mention of new fundraising through debt or equity in the transcript.
→The company reported that for the full year FY26, they did not utilize any working capital limits except letters of credit and bank guarantees.
→Capex for FY26 was INR152 crores funded internally, focusing on Ambernath and smaller projects.
→For the Patalganga facility, an estimated capex of INR200 crores is planned over the next 2 years.
→No discussion on raising new debt or equity to fund this; emphasis appears on internal accruals and disciplined financial management.
→Overall, no indication or announcement of fresh fundraising via debt or equity in the near term from the transcripts provided.

Order book

Yes

→Cardiovascular intermediate: Advanced discussions for 300 metric tons capacity, expected to be nearly fully utilized in FY27, but full potential to scale over 2-3 years.
→Contracts locked with 3-4 large customers for the cardiovascular product.
→Liquid anesthetic (sevoflurane formulation): CMO discussions at advanced stage, but no firm term sheet signed yet.
→DSM contract stabilized with around 3 tons/month volume; contributing approx. INR30-35 crores in FY26 with peak expected at INR60 crores in FY27.
→No signed agreement yet for GLP-1 product development; discussions are at an advanced stage.
→New product launches and existing basket growing steadily.
→No use of PLI scheme; focusing on customer qualification and dossier inclusion.
→Order book for cardiovascular and other products contributing to gradual scale-up but no immediate large jumps in revenue for FY27 from new technologies/products.

Capex plans

Yes

→Continued capacity expansion with the addition of the F block at Lote Parshuram plant, adding 150-200 KL capacity over the next 2 years with INR40-50 crores capex.
→Development of the Patalganga facility with all clearances received; Phase 1 includes two API/advanced intermediate blocks and two formulation blocks, planned capex around INR200 crores over the next 2 years.
→Focus on capacity building to support growth, especially for CMO/CDMO opportunities and to handle scaling product volumes.
→Total capex for FY26 was INR152 crores, mainly spent on Ambernath facility, maintenance, Ribo Block, and formulation plant needs.
→R&D investments have doubled with new labs at Lote and Ambernath focusing on new APIs, formulations, and CMO/CDMO areas.
→Further capex expected to support backing integration, new product launches, and strategic growth segments like cardiovascular and anesthetics.

How does Supriya Lifesci. rank vs peers in ?

Pro feature

1Supriya Lifesci.

Rev 2Mar 3

See full sector rankings

Supriya Lifesci. Q4 FY26 Earnings Call Analysis

Revenue guidance

Margin guidance

Fundraise plans

Order book

Capex plans

Supriya Lifesci. Q4 FY26 Earnings Call Analysis

Revenue guidance

Margin guidance

Fundraise plans

Order book

Capex plans

Continue your research

What Supriya Lifesci.'s management said in earlier quarters